Amendments to the Claims

Claims 1-5 (Cancelled)

Claim 6 (Previously Presented): A method for stimulating production of antibodies with catalytic activity comprising:

a) administering to a test subject, an immunogenic amount of a covalently reactive antigen analog (CRAA);

b) repeating step a) as necessary to ensure effective antibody production; and

c) isolating and purifying said antibodies;

wherein said covalently reactive antigen analog contains an electrophilic center flanked by peptide residues derived from proteins associated with a peptide antigen to be targeted for cleavage.

Claim 7 (Cancelled)

Claim 8 (Original): A method of stimulating production of catalytic antibodies as claimed in claim 6, wherein an immunogenic amount of a transition state analog (TSA) is co-administered with said CRAA.

Claims 9-11 (Cancelled)

Claim 12 (Previously Presented): A method for passively immunizing a patient, comprising:

a) administering to said patient a catalytic antibody specific for an antigen associated with a medical disorder diagnosed in said patient, said catalytic antibody being produced by the method of claim 6;

b) repeating step a) as necessary to maintain immunity; and

c) assessing said patient's sera for the presence of catalytic antibodies.

Claim 13 (Previously Presented): A method for actively immunizing a patient, against a microbial infection, comprising:

a) complexing a covalently reactive antigen analog (CRAA) comprising an immunogenic microbial epitope from an infectious organism with an adjuvant, said CRAA-epitope-adjuvant complex comprising a vaccine;

b) administering said vaccine to said patient in a dose in the range of 100-1000 micrograms/kg body weight;

c) administering at least one booster injection, said at least one booster injections being administered at four week intervals; and

d) assessing said patient's sera for the presence of catalytic antibodies against said microbial epitope.